Therapeutic management of incident patients with anemia of NDD-CKD during the first year after the index date (patients with ≥1 treatment of interest).</p
<p>SD = standard deviation; 95% CI = confidence interval; adj. OR = adjusted OR; mean duration o...
Anemia in chronic kidney disease is a prevalent and expensive problem in the United States, and it i...
<p>The weighted percentages reflect the frequency of treatment of anemia among people within each st...
Incidence and prevalence of anemia among patients with NDD-CKD in the EGB database per year (2015–20...
Anemia is a frequently encountered problem of chronic kidney disease (CKD) and deteriorates as renal...
<p>Annualized anemia treatment decision flowchart assumed in the CKD Policy Model.</p
<p>Use of psychotropic agents 1 year before and after the index date, with or without acute admissio...
<p>Incremental cost-effectiveness as a function of anemia treatment targets in persons with CKD stag...
Therapeutic features of CKD-MBD of study cohort, overall and by CKD stage, at baseline.</p
Anemia is a frequently encountered problem of chronic kidney disease (CKD) and deteriorates as renal...
Recently, the Kidney Disease: Improving Global Outcomes (KDIGO) group has produced comprehensive cli...
CKD stage not available for all patients. Incident missing n/total N (%): 2015, 74/386 (19.2%); 2016...
<p>Demographics, biochemistry and therapy in healthy volunteers and CKD patients across stages.</p
Incidence and prevalence of anemia among patients with confirmed + possible NDD-CKD in the EGB datab...
Abstract: Anemia is a frequent complication of chronic kidney disease (CKD). Anemia of CKD develops ...
<p>SD = standard deviation; 95% CI = confidence interval; adj. OR = adjusted OR; mean duration o...
Anemia in chronic kidney disease is a prevalent and expensive problem in the United States, and it i...
<p>The weighted percentages reflect the frequency of treatment of anemia among people within each st...
Incidence and prevalence of anemia among patients with NDD-CKD in the EGB database per year (2015–20...
Anemia is a frequently encountered problem of chronic kidney disease (CKD) and deteriorates as renal...
<p>Annualized anemia treatment decision flowchart assumed in the CKD Policy Model.</p
<p>Use of psychotropic agents 1 year before and after the index date, with or without acute admissio...
<p>Incremental cost-effectiveness as a function of anemia treatment targets in persons with CKD stag...
Therapeutic features of CKD-MBD of study cohort, overall and by CKD stage, at baseline.</p
Anemia is a frequently encountered problem of chronic kidney disease (CKD) and deteriorates as renal...
Recently, the Kidney Disease: Improving Global Outcomes (KDIGO) group has produced comprehensive cli...
CKD stage not available for all patients. Incident missing n/total N (%): 2015, 74/386 (19.2%); 2016...
<p>Demographics, biochemistry and therapy in healthy volunteers and CKD patients across stages.</p
Incidence and prevalence of anemia among patients with confirmed + possible NDD-CKD in the EGB datab...
Abstract: Anemia is a frequent complication of chronic kidney disease (CKD). Anemia of CKD develops ...
<p>SD = standard deviation; 95% CI = confidence interval; adj. OR = adjusted OR; mean duration o...
Anemia in chronic kidney disease is a prevalent and expensive problem in the United States, and it i...
<p>The weighted percentages reflect the frequency of treatment of anemia among people within each st...